Ivonescimab for the Treatment of Thymic Cancer

Part of paid clinical trials in Davis, California.

Sponsor
Jonsson Comprehensive Cancer Center
Study ID
NCT06980077
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Thymus Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Biopsy Procedure — PROCEDURE
    Undergo biopsy
  • Biospecimen Collection — PROCEDURE
    Undergo collection of blood and urine samples
  • Computed Tomography — PROCEDURE
    Undergo CT
  • Ivonescimab — BIOLOGICAL
    Given IV
  • Magnetic Resonance Imaging — PROCEDURE
    Undergo MRI
  • Questionnaire Administration — OTHER
    Ancillary studies

Study Details

This phase II trial tests how well ivonescimab works in treating patients with thymic carcinoma. Immunotherapy with monoclonal antibodies, such as ivonescimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Key Dates

Start date
Jul 15, 2025
Status verified
May 2025
Primary completion
Jun 17, 2027
Completion
Jun 17, 2028

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (ivonescimab)
    Patients receive ivonescimab IV over 60-120 minutes on day 1 of each cycle. Cycles repeat Q3W for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and collection of blood and urine samples throughout the study. Patients may undergo MRI throughout the study if indicated and may optionally undergo a biopsy at the end of treatment.

Primary Outcome Measure

Overall response rate (ORR) [ Time Frame: Up to 1 year ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
University of California at Davis (UCD)DavisCalifornia95817
Hildy Donner
[email protected]
Surbhi Singhai, MD (PRINCIPAL_INVESTIGATOR)
University of California at Irvine (UCI)IrvineCalifornia92868
Keagan Buttigieg
[email protected]
Zhaohui Ann Arter, MD (PRINCIPAL_INVESTIGATOR)
UCLA / Jonsson Comprehensive Cancer CenterLos AngelesCalifornia90095
Kim Nahyun
[email protected]
310-633-8400
Jonathan W. Goldman (PRINCIPAL_INVESTIGATOR)
University of California at San Francisco (UCSF)San FranciscoCalifornia94115
Isabelle Remick
[email protected]
Matthew Grubens, MD (PRINCIPAL_INVESTIGATOR)
Dana Farber Cancer InstituteBostonMassachusetts02115
Justine Olegario
[email protected]
Jennifer Marks, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Davis, CA

By research site
University of California at Davis (UCD)· Davis, CAUniversity of California at Irvine (UCI)· Irvine, CAUCLA / Jonsson Comprehensive Cancer Center· Los Angeles, CAUniversity of California at San Francisco (UCSF)· San Francisco, CADana Farber Cancer Institute· Boston, MA

Related Studies